EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Exploring MHC class II I-Ab blockade as a potential treatment for Sjögren’s disease in the mouse model

Alexandria Voigt iD, Shivai Gupta, Yiran Shen iD, Patricia Glenton, Danmeng Li iD, David Ostrov iD, I Bhattacharyya iD, Cuong Q Nguyen iD

ImmunoHorizons · 2025

DOI: 10.1093/immhor/vlaf030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoHorizons, 2025. Verfasst von Alexandria Voigt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL, United States. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Metformin, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCR NIH HHS, National Institutes of Health, National Institute of Dental and Craniofacial Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sjögren’s disease (SjD) is a chronic autoimmune disorder predominantly affecting females, characterized by exocrine gland dysfunction. This study investigates the therapeutic potential of 2-chloro-1-(4-hydroxy-phenyl)-ethanone (CHPE) and metformin in the C57BL/6.NOD-Aec1Aec2 mouse model, which closely mirrors human SjD. Molecular docking identified CHPE and metformin as high-affinity binders to the MHC class II I-Ab antigen-binding groove, suggesting their ability to inhibit antigen presentation and modulate immune responses. In-vitro assays confirmed their effectiveness in reducing T cell activation. In-vivo studies demonstrated that both preventative and therapeutic regimens of CHPE and metformin significantly reduced lymphocytic infiltration in the lacrimal glands, with metformin showing a more pronounced effect in females. Salivary gland infiltration was less responsive, though some reduction in focal scores was observed in male mice treated preventatively with CHPE. Both drugs altered the composition of lymphocytic infiltrates, particularly by reducing B cell populations, with notable sex-specific differences in response to treatment. CHPE and metformin also reduced anti-nuclear antibody levels, with CHPE showing stronger effects in females. Additionally, both drugs improved saliva and tear secretion, with metformin being more effective in the preventative regimen, especially in females. T cell receptor transductant assays revealed that CHPE and metformin exert their therapeutic effects through antigen-specific pathways, inhibiting T cell responses to SjD-associated autoantigens. Overall, this study provides compelling evidence that CHPE and metformin can modulate immune responses and improve gland function, with effectiveness varying by sex and age. These findings support the potential of these compounds as personalized treatments for SjD tailored to individual patient characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeMetforminHistocompatibility Antigens Class IIAnimalsFemaleMiceDisease Models, AnimalMaleMice, Inbred NODMice, Inbred C57BLHumansMolecular Docking SimulationT-LymphocytesLymphocyte ActivationB-LymphocytesLacrimal ApparatusAntigen Presentation

Stichwörter der Autor:innen

CHPEMHCMetforminSjögren’s Diseasein-silico docking

Substanzen

MetforminHistocompatibility Antigens Class II

Autor:innen und Institutionen

  • Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL, United States.
  • Department of Pathology, Immunology & Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, United States.
  • Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida, Gainesville, FL, United States.
  • Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, United States.
  • Center of Orphaned Autoimmune Diseases, University of Florida, Gainesville, FL, United States.

ORCID-Profile: Alexandria Voigt, Yiran Shen, Danmeng Li, David Ostrov, I Bhattacharyya, Cuong Q Nguyen

Förderung

  • NIDCR NIH HHS
  • National Institutes of Health
  • National Institute of Dental and Craniofacial Research

Zitieren

APA

Voigt, A., Gupta, S., Shen, Y., Glenton, P., Li, D., Ostrov, D., Bhattacharyya, I., & Nguyen, C. Q. (2025). Exploring MHC class II I-Ab blockade as a potential treatment for Sjögren’s disease in the mouse model. ImmunoHorizons. https://doi.org/10.1093/immhor/vlaf030

Vancouver

Voigt A, Gupta S, Shen Y, Glenton P, Li D, Ostrov D, et al. Exploring MHC class II I-Ab blockade as a potential treatment for Sjögren’s disease in the mouse model. ImmunoHorizons. 2025. doi:10.1093/immhor/vlaf030

BibTeX
@article{Voigt2025,
  author = {Voigt, Alexandria and Gupta, Shivai and Shen, Yiran and Glenton, Patricia and Li, Danmeng and Ostrov, David and Bhattacharyya, I and Nguyen, Cuong Q},
  title = {Exploring MHC class II I-Ab blockade as a potential treatment for Sjögren’s disease in the mouse model},
  journal = {ImmunoHorizons},
  year = {2025},
  doi = {10.1093/immhor/vlaf030}
}
Kostenlos starten →